Palvella Therapeutics (PVLA) Other Non-Current Liabilities (2013 - 2026)
Palvella Therapeutics (PVLA) reported Other Non-Current Liabilities of $2.2 million for Q1 2026, up 25.26% year-over-year from $1.7 million in Q1 2025, and up 5.68% on a QoQ basis from $2.0 million in Q4 2025.
Palvella Therapeutics (PVLA) has 12 years of Other Non-Current Liabilities data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 25.26% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 25.26% YoY) and the FY2025 annual result came in at $2.0 million, up 23.92% from the prior year.
- Other Non-Current Liabilities improved to $2.2 million in Q1 2026 per PVLA's latest filing, from $2.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.2 million in Q1 2026 and bottomed at $1.0 million in Q4 2023.
- The 4-year median for Other Non-Current Liabilities is $1.8 million (2025), against an average of $1.8 million.
- The widest annual swing landed in 2024, when Other Non-Current Liabilities surged 62.43%; it then increased 23.92% in 2025.
- Tracing PVLA's Other Non-Current Liabilities over 4 years: stood at $1.0 million in 2023, then surged by 62.43% to $1.6 million in 2024, then climbed by 23.92% to $2.0 million in 2025, then climbed by 5.68% to $2.2 million in 2026.
- Per Business Quant, the three latest PVLA Other Non-Current Liabilities figures stand at $2.2 million (Q1 2026), $2.0 million (Q4 2025), and $1.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.16 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 1.92 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.72 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Dec 31, 2020 | 6,000.00 |
| Sep 30, 2019 | 12.08 Mn |
| Jun 30, 2019 | 12.32 Mn |
| Mar 31, 2019 | 27,000.00 |
| Dec 31, 2018 | 27,000.00 |
| Sep 30, 2018 | 32,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Mar 31, 2018 | 37,000.00 |
| Dec 31, 2017 | 37,000.00 |
| Sep 30, 2017 | 43,462.00 |
| Jun 30, 2017 | 42,862.00 |
| Mar 31, 2017 | 42,086.00 |
| Dec 31, 2016 | 47,000.00 |
| Sep 30, 2016 | 44,565.00 |
| Jun 30, 2016 | 42,063.00 |
| Mar 31, 2016 | 39,742.00 |
| Dec 31, 2015 | 23,852.00 |
| Sep 30, 2015 | 308,071.00 |
| Jun 30, 2015 | 307,850.00 |
| Mar 31, 2015 | 296,452.00 |
| Dec 31, 2014 | 6,051.00 |
| Dec 31, 2013 | 379,942.00 |